

Anna L Zignego

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6488016/anna-l-zignego-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

7,602
citations

50
h-index

81
g-index

189
ext. papers

8,420
ext. citations

5.8
avg. IF

5.37
L-index

#	Paper	IF	Citations
180	Reply.. <i>Hepatology</i> , 2022 ,	11.2	
179	A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.. <i>Hepatology</i> , 2021 ,	11.2	3
178	Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
177	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients subgroups. <i>Journal of Autoimmunity</i> , 2021 , 125, 102744	15.5	19
176	Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome. <i>Minerva Gastroenterology</i> , 2021 , 67, 218-226	3	3
175	REPLY. <i>Hepatology</i> , 2021 , 74, 2910	11.2	1
174	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021 , 13,	6.2	4
173	Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. <i>Hepatology</i> , 2021 , 74, 1164-1173	11.2	3
172	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab Biosimilar). <i>Internal and Emergency Medicine</i> , 2021 , 16, 149-156	3.7	7
171	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021 , 53, 612-619	3.3	3
170	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , 2021 , 41, 133-149	7.9	1
169	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021 , 60, 4418-4427	3.9	1
168	Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
167	Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. <i>Autoimmunity Reviews</i> , 2021 , 102923	13.6	1
166	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021 , 27, 4245-4252	3.3	5
165	SARS-CoV-2 was already circulating in Italy, in early December 2019. <i>European Review for Medical and Pharmacological Sciences</i> , 2021 , 25, 3342-3349	2.9	3
164	A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. <i>Genes and Immunity</i> , 2020 , 21, 131-135	4.4	3

163 Fibrosis Assessment in Patients with HCV or HBV Chronic Infection **2020**, 113-121

162 Role of Notch Receptors in Hematologic Malignancies. *Cells*, **2020**, 10, 7.9 3

161 Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. *Current Medical Research and Opinion*, **2020**, 36, 245-249 2.5 9

160 Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia. *Journal of Immunological Methods*, **2020**, 476, 112687 2.5 5

159 Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. *Liver International*, **2019**, 39, 628-632 7.9 19

158 Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. *Current Medical Research and Opinion*, **2019**, 35, 661-666 2.5 1

157 Real life experiences in HCV management in 2018. *Expert Review of Anti-Infective Therapy*, **2019**, 17, 117-128 5.3 5

156 Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Infection*, **2019**, 47, 141-168 5.8

155 Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. *Journal of Viral Hepatitis*, **2018**, 25, 811-817 3.4 19

154 Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients. *Digestive and Liver Disease*, **2018**, 50, 938-943 3.3 7

153 Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice. *Liver International*, **2018**, 38, 183 7.9 4

152 Cryoglobulinaemia. *Nature Reviews Disease Primers*, **2018**, 4, 11 51.1 76

151 Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 440-450 6.1 17

150 Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. *Liver International*, **2018**, 38, 2190-2198 7.9 23

149 Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. *Acta Biomedica*, **2018**, 89, 321-332 12 5

148 Current and future challenges in HCV: insights from an Italian experts panel. *Infection*, **2018**, 46, 147-163 5.8 3

147 Expert opinion on managing chronic HCV in patients with mixed cryoglobulinaemia vasculitis. *Antiviral Therapy*, **2018**, 23, 1-9 1.6 6

146 Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Internal and Emergency Medicine*, **2018**, 13, 1139-1166 3.7 2

145	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , 2018 , 31, 695-710	4.8	3
144	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> , 2018 , 50, 1133-1152	3.3	2
143	Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. <i>Clinical and Experimental Hepatology</i> , 2018 , 4, 197-200	2.2	8
142	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
141	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017 , 66, 1282-1299	13.4	58
140	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
139	Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. <i>European Journal of Pharmacology</i> , 2017 , 806, 105-109	5.3	19
138	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017 , 16, 523-541	13.6	66
137	Reply. <i>Hepatology</i> , 2017 , 65, 1771-1772	11.2	8
136	Free light chains: Eclectic multipurpose biomarker. <i>Journal of Immunological Methods</i> , 2017 , 451, 11-19	2.5	24
135	IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. <i>Digestive and Liver Disease</i> , 2017 , 49, 1233-1239	3.3	11
134	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017 , 66, 1814-1825	11.2	18
133	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
132	Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. <i>Arthritis Research and Therapy</i> , 2017 , 19, 44	5.7	6
131	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017 , 12, e0172159	3.7	31
130	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017 , 12, e0185728	3.7	28
129	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. <i>Oncotarget</i> , 2017 , 8, 71528-71535	3.3	6
128	Treatment of HCV-Related Mixed Cryoglobulinemia. <i>Current Drug Targets</i> , 2017 , 18, 794-802	3	12

127	HCV-Related Rheumatic Manifestations and Therapeutic Strategies. <i>Current Drug Targets</i> , 2017 , 18, 803-810	5
126	Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study. <i>Current Drug Targets</i> , 2017 , 18, 772-785	39
125	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016 , 15, 1145-1160	13.6 69
124	Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. <i>Digestive and Liver Disease</i> , 2016 , 48, 927-33	3.3 14
123	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3 12
122	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. <i>Oncotarget</i> , 2016 , 7, 37487-37497	3.3 15
121	Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. <i>Digestive and Liver Disease</i> , 2016 , 48, 780-4	3.3 39
120	A randomized, controlled study of peginterferon lambda-1a/ribavirin + daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016 , 5, 1365	3
119	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , 2016 , 64, 1473-1482	11.2 138
118	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. <i>Journal of Autoimmunity</i> , 2015 , 63, 88-93	15.5 30
117	Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. <i>Case Reports in Immunology</i> , 2015 , 2015, 816424	1.9 23
116	Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. <i>PLoS ONE</i> , 2015 , 10, e0117420	3.7 40
115	Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. <i>Hepatology International</i> , 2015 , 9, 586-93	8.8 6
114	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015 , 61, 1145-53	11.2 98
113	Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. <i>BMJ, The</i> , 2015 , 350, h3363	5.9 4
112	Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. <i>Liver International</i> , 2015 , 35, 2100-7	7.9 13
111	MicroRNA expression in hepatitis C virus-related malignancies: A brief review. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8562-8	5.6 9
110	Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. <i>World Journal of Hepatology</i> , 2015 , 7, 327-43	3.4 91

109	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015 , 14, 889-96	13.6	43
108	Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials. <i>Digestive and Liver Disease</i> , 2015 , 47, 988-93	3.3	33
107	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 15-31	5.1	62
106	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3013-9	5.6	10
105	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , 2014 , 12, 21	8.5	12
104	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014 , 15, 500-5	4.4	43
103	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014 , 46, 833-7	3.3	54
102	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014 , 53, 2209-13	3.9	55
101	Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. <i>BioMed Research International</i> , 2014 , 2014, 710642	3	10
100	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2014 , 46 Suppl 5, S165-73	3.3	186
99	Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. <i>Clinical Rheumatology</i> , 2013 , 32, 1147-54	3.9	11
98	Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. <i>Digestive and Liver Disease</i> , 2013 , 45, 840-3	3.3	41
97	Hepatitis C-associated B-cell non-Hodgkin lymphomas: the emerging role of miRNA-26b. <i>Journal of Hepatology</i> , 2013 , 59, 1362-3	13.4	7
96	Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. <i>PLoS ONE</i> , 2013 , 8, e62965	3.7	35
95	Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. <i>Journal of Viral Hepatitis</i> , 2013 , 20, e107-14	3.4	15
94	High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. <i>International Journal of Immunopathology and Pharmacology</i> , 2013 , 26, 49-57	3	6
93	Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8910-5	5.6	14
92	A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 843-53		268

91	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. <i>Journal of Translational Medicine</i> , 2012 , 10, 158	8.5	11
90	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , 2012 , 7 Suppl 3, S201-8	3.7	37
89	The Expanding Spectrum of Clinical Features in HCV-Related Mixed Cryoglobulinemia 2012 , 155-162		2
88	HCV and lymphoproliferation. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 980942		73
87	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S48-52	2.2	25
86	The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 525-32	3.4	12
85	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011 , 10, 444-54	13.6	165
84	A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. <i>Autoimmunity Reviews</i> , 2011 , 10, 714-9	13.6	55
83	Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. <i>Autoimmunity Reviews</i> , 2011 , 11, 48-55	13.6	135
82	Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1446-51		50
81	Preliminary classification criteria for the cryoglobulinaemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1183-90	2.4	97
80	Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 933-41	2.2	31
79	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010 , 116, 335-42	2.2	97
78	Hepatitis C virus RNA localization in human carotid plaques. <i>Journal of Clinical Virology</i> , 2010 , 47, 72-5	14.5	114
77	Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool?. <i>Digestive and Liver Disease</i> , 2009 , 41, 863-6	3.3	23
76	HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation. <i>Autoimmunity Reviews</i> , 2008 , 8, 107-11	13.6	29
75	Extrahepatic manifestations of hepatitis C virus infection. <i>Clinics in Liver Disease</i> , 2008 , 12, 611-36, ix	4.6	52
74	Hepatitis C virus (HCV) infection: a systemic disease. <i>Molecular Aspects of Medicine</i> , 2008 , 29, 85-95	16.7	67

73	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. <i>Journal of Hepatology</i> , 2008 , 49, 170-4	13.4	25
72	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008 , 111, 2943-5	2.2	23
71	Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?. <i>Blood</i> , 2008 , 112, 4353-4	2.2	20
70	Involvement of PI3K in HCV-related lymphoproliferative disorders. <i>Journal of Cellular Physiology</i> , 2008 , 214, 396-404	7	17
69	HCV-related autoimmune and neoplastic disorders: the HCV syndrome. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S13-21	3.3	82
68	HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S55-60	3.3	58
67	Hepatitis C virus core protein enhances B lymphocyte proliferation. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S72-5	3.3	12
66	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S76-82	3.3	8
65	HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S107-11	3.3	26
64	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S129-33	3.3	17
63	Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. <i>Digestive and Liver Disease</i> , 2007 , 39, 2-17	3.3	183
62	Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 22-8	3.4	9
61	B-cells and mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , 2007 , 7, 114-20	13.6	51
60	Role of the HLA class II: HCV-related disorders. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1107, 308-18	6.5	16
59	Hepatitis C virus lymphotropism: lessons from a decade of studies. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S38-45	3.3	64
58	Hepatitis C virus-related lymphoproliferative disorders: an overview. <i>World Journal of Gastroenterology</i> , 2007 , 13, 2467-78	5.6	87
57	Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. <i>Hepatology</i> , 2006 , 43, 1166-7; author reply 1167-8	11.2	34
56	Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 402-8	3.4	54

55	Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. <i>Oncology Reports</i> , 2006 , 15, 1305-8	3.5	16
54	JH6 gene usage among HCV-associated MALT lymphomas harboring t(14;18) translocation. <i>Journal of Immunology</i> , 2005 , 174, 3839; author reply 3839	5.3	7
53	Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. <i>Cancer Biology and Therapy</i> , 2005 , 4, 1192-4	4.6	25
52	Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2004 , 33, 355-74	5.3	365
51	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003 , 102, 1196-201	2.2	79
50	HCV infection, malignancy, and liver transplantation. <i>Transplantation Proceedings</i> , 2003 , 35, 1032-3	1.1	3
49	HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. <i>Clinical and Experimental Rheumatology</i> , 2003 , 21, S78-84	2.2	25
48	Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. <i>Annals of Internal Medicine</i> , 2002 , 137, 571-80	8	145
47	Cryoglobulins. <i>Journal of Clinical Pathology</i> , 2002 , 55, 4-13	3.9	243
46	Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways. <i>Journal of General Virology</i> , 2002 , 83, 1665-1671	4.9	15
45	Erectile dysfunction and hepatitis C virus infection. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 698-9	27.4	45
44	Thyroid cancer in HCV-related mixed cryoglobulinemia patients. <i>Clinical and Experimental Rheumatology</i> , 2002 , 20, 693-6	2.2	36
43	Relation between infection and autoimmunity in mixed cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , 2000 , 12, 53-60	5.3	63
42	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000 , 31, 474-9	11.2	136
41	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. <i>Translational Research</i> , 1999 , 134, 68-73		46
40	Extrahepatic manifestations of HCV infection: facts and controversies. <i>Journal of Hepatology</i> , 1999 , 31, 369-76	13.4	119
39	Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. <i>Hepatology</i> , 1998 , 28, 211-8	11.2	85
38	Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. <i>Annals of Internal Medicine</i> , 1998 , 129, 294-8	8	83

37	Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. <i>Lupus</i> , 1998 , 7, 275-9	2.6	78
36	Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. <i>British Journal of Rheumatology</i> , 1997 , 36, 360-5		58
35	Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkin's lymphoma. <i>Acta Haematologica</i> , 1997 , 98, 89-94	2.7	12
34	Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. <i>Archives of Virology</i> , 1997 , 142, 535-44	2.6	37
33	Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. <i>Archives of Virology</i> , 1997 , 142, 545-55	2.6	83
32	Could HGV infection be implicated in lymphomagenesis?. <i>British Journal of Haematology</i> , 1997 , 98, 778-94.5		15
31	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997 , 51, 313-318	19.7	62
30	Hepatitis-C-virus infection and cancer. <i>International Journal of Cancer</i> , 1997 , 71, 1113-5	7.5	14
29	Lack of preferential localization of tumoral mass in B-cell non-Hodgkin's lymphoma associated with hepatitis C virus infection. <i>Blood</i> , 1997 , 89, 3066-8	2.2	3
28	Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. <i>Clinical and Experimental Rheumatology</i> , 1997 , 15, 711-2	2.2	22
27	Chronic hepatitis C and B-cell non-Hodgkin's lymphoma. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996 , 89, 117-22	2.7	26
26	Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1074-5		24
25	Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. <i>Annals of Internal Medicine</i> , 1996 , 124, 31-4	8	126
24	Hepatitis C Virus Lymphotropism and Possible Pathogenetic Implications. 1996 , 251-259		
23	Monoclonal gammopathy in patients with chronic hepatitis C virus infection. <i>Blood</i> , 1996 , 88, 1122	2.2	9
22	Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. <i>Journal of Rheumatology</i> , 1996 , 23, 1641-3	4.1	34
21	Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , 1995 , 346, 1426-7	4.0	74
20	Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. <i>Journal of Medical Virology</i> , 1995 , 47, 58-64	19.7	73

19	Mixed cryoglobulinemia as a possible preneoplastic disorder. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1859-60	45
18	Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. <i>Clinical and Experimental Rheumatology</i> , 1995 , 13 Suppl 13, S33-7	2.2 6
17	Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. <i>Clinical and Experimental Rheumatology</i> , 1995 , 13 Suppl 13, S135-40	2.2 9
16	Hepatitis C virus and mixed cryoglobulinaemia. <i>Rheumatology</i> , 1994 , 33, 301	3.9 5
15	Non-Hodgkin's lymphoma: possible role of hepatitis C virus. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 272, 355-6	27.4 35
14	"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. <i>Hepatology</i> , 1994 , 19, 577-82	11.2 39
13	Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1994 , 88, 392-4	4.5 392
12	Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia. <i>European Journal of Clinical Investigation</i> , 1994 , 24, 781-4	4.6 71
11	Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. <i>Journal of Internal Medicine</i> , 1994 , 236, 31-6	10.8 38
10	Hepatitis C virus infection and B-cell lymphomas. <i>European Journal of Cancer</i> , 1994 , 30A, 1591-2	7.5 30
9	Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma. <i>Clinical and Experimental Rheumatology</i> , 1994 , 12, 89-90	2.2 11
8	Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus. <i>American Journal of Nephrology</i> , 1993 , 13, 300-4	4.6 52
7	Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. <i>European Journal of Clinical Investigation</i> , 1993 , 23, 851-5	4.6 72
6	Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. <i>Infection</i> , 1993 , 21, 93-7	5.8 29
5	Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. <i>Blood</i> , 1993 , 82, 3701-4	2.2 46
4	Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. <i>Blood</i> , 1993 , 81, 1132-6	2.2 34
3	Infection of peripheral mononuclear blood cells by hepatitis C virus. <i>Journal of Hepatology</i> , 1992 , 15, 382-6	13.4 365
2	Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. <i>Clinical and Experimental Rheumatology</i> , 1991 , 9, 23-8	2.2 5

